SMAD3 is a transcriptional modulator activated by transforming growth factor β (TGF-β) [66], [67] and has been reported to be marginally associated with coronary artery disease, of which low HDL-C levels is a risk factor [68]. Here, SMAD3 is linked to coronary artery disorder.